CPhI Worldwide has formally introduced a new co-located event entirely dedicated to Finished Dosage Formulation (FDF) following a soft launch amongst exhibitors in 2015. This new event will open at the 27th CPhI Worldwide in Barcelona being held from October 4-6, 2016 and reflects the huge growth in finished dosage formulations across the wider pharma market. The next stage in the pharma event’s introduction is to target new potential visitors and attendees through a sustained marketing and branding effort.

FDF will gather together the entire supply chain in one location at CPhI WW, from Big Pharma and CMO, to out-licensing and dossier specialists, end product distributors, generic pharma companies, and home markets. It will act as a global meeting-point for any company looking to grow, launch or distribute finished formulations in international or national markets.

Over the last few years, sales in the pharmaceutical supply chain have accelerated across commercial supply and final dosage forms, where more complex solutions and higher margin products are common. Pharma companies seeking partners with new formulations, and the rise in complex and difficult to formulate compounds are driving the growth in this market.

According to CphI, generics and the increasing use of out-licensed formulations are a key factor behind its decision. In fact, since the introduction of the FDF zone at CPhI Worldwide in 2011, it has quickly grown to be the third largest part of the show totalling over 11,000 m2 in 2015.

Dosage forms represented will cover all types of solid dose, semi-solids, liquids, sprays and steriles from both pharma and biologics companies, including tablets, capsules, gels, parenteral drugs, vials, patches, creams, inhalation, nasal, sublingual and suppository.

Says Rutger Oudejans, brand director, pharma at UBM EMEA “Finished dose formulations are already a huge part of CPhI Worldwide. And, both within the wider market and in terms of exhibitor numbers, it is one of the fastest growing areas in pharma. Our aim in 2016 is to cement FDF’s reputation as the essential platform for launching and conducting business in the global finished dose market.”

FDF will be supported by its own dedicated content, and a more prescriptive 1-2-1 matchmaking platform – which will enable professionals within this supply chain to explore the latest developments, strategies and market analysis. Topics will include everything from the regulatory approvals, processes and changes, to key growth markets, new formulation technologies, distribution and commercialisation.